http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-108261414-B
Outgoing Links
| Predicate | Object |
|---|---|
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-4725 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-473 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-473 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-4725 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P11-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-00 |
| filingDate | 2018-01-11-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate | 2019-09-06-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationDate | 2019-09-06-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | CN-108261414-B |
| titleOfInvention | A kind of pharmaceutical composition for treating lung cancer |
| abstract | The invention discloses a kind of pharmaceutical compositions for treating lung cancer.The pharmaceutical composition contains the Bcl-xl inhibitor A-1331852 and fluorescence probe NA-2a for treating upper effective dose.In the pharmaceutical composition, fluorescence probe NA-2a and Bcl-xl inhibitor A-1331852 synergistic effect, cell permeability is opened by fluorescence probe NA-2a, under the premise of not destroying the function of Bcl-xl inhibitor A-1331852 and guaranteeing cell integrity, helps Bcl-xl inhibitor A-1331852 to enter in cell and play a role to reach significantly more treatment lung cancer effect.Vitro Experimental Results show that for A549 cell strain, the inhibiting rate of pharmaceutical composition of the present invention improves 20-30% compared with single use Bcl-xl inhibitor A-1331852, improves 60% or more compared with single use fluorescence probe NA-2a. |
| priorityDate | 2018-01-11-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 46.